Eupraxia Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:EPRX Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
20 Feb 26	BuyUS$1,960,491	Joseph Freedman	Individual	280,000	US$7.00
24 Nov 25	BuyUS$101,923	Paul Brennan	Individual	16,300	US$6.30
24 Sep 25	BuyUS$16,786	Simon Pimstone	Individual	3,052	US$5.50
24 Sep 25	BuyUS$1,324,318	Joseph Freedman	Individual	240,785	US$5.50
24 Sep 25	BuyUS$370,002	John Montalbano	Individual	67,273	US$5.50
24 Sep 25	BuyUS$18,497	Michael Wilmink	Individual	3,363	US$5.50
23 Sep 25	BuyUS$27,115	Richard Glickman	Individual	4,930	US$5.50
18 Jun 25	BuyUS$134,947	Joseph Freedman	Individual	33,400	US$4.34

Insider Trading Volume

Insider Buying: EPRX insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of EPRX?
Owner Type	Number of Shares	Ownership Percentage
Hedge Funds	4,720,144	7.85%
Individual Insiders	11,095,145	18.5%
Institutions	14,866,002	24.7%
General Public	29,444,523	49%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 68.8%.

Top Shareholders

Top 25 shareholders own 47.93% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
7.85%	Manchester Management Company, LLC	4,720,144	US$37.7m	-15.2%	77.53%
6.17%	Beutel Goodman & Company Ltd.	3,709,373	US$29.7m	-8.61%	0.15%
5.93%	Robert Disbrow	3,568,150	US$28.5m	0%	no data
4.2%	Joseph Freedman	2,524,230	US$20.2m	21.7%	no data
2.55%	John Montalbano	1,536,139	US$12.3m	18.9%	no data
2.25%	Vivo Capital, LLC	1,350,000	US$10.8m	0%	0.6%
2.25%	Balyasny Asset Management L.P.	1,350,000	US$10.8m	0%	0.02%
2.14%	Scotiabank Global Banking and Markets, Asset Management Division	1,286,183	US$10.3m	0.65%	0.04%
2%	Great Point Partners, LLC	1,200,000	US$9.6m	0%	2.46%
1.84%	Alexander Rothwell	1,104,000	US$8.8m	36.3%	no data
1.46%	James Helliwell	875,012	US$7.0m	29.8%	no data
1.18%	Point72 Asset Management, L.P.	712,104	US$5.7m	0%	0.01%
1.01%	Ikarian Capital, LLC	610,000	US$4.9m	0%	0.64%
0.89%	IG Investment Management, Ltd.	533,210	US$4.3m	0%	0.01%
0.83%	Squadron Capital Management Llc	500,000	US$4.0m	0%	1.65%
0.78%	Matco Financial, Inc.	467,000	US$3.7m	0%	1.2%
0.66%	Ally Bridge Group	397,895	US$3.2m	-56.5%	1.27%
0.59%	Velan Capital Partners LP	352,000	US$2.8m	0%	1.72%
0.57%	Paul Geyer	340,346	US$2.7m	0%	no data
0.52%	Ann Rothwell	315,060	US$2.5m	0%	no data
0.51%	Morgan Frank	307,306	US$2.5m	0%	no data
0.5%	Affinity Asset Advisors, LLC	300,000	US$2.4m	0%	0.17%
0.46%	Arrowstreet Capital, Limited Partnership	278,064	US$2.2m	0%	no data
0.42%	Merrill Lynch, Pierce, Fenner & Smith Incorporated	253,221	US$2.0m	493%	no data
0.38%	Michael Wilmink	228,228	US$1.8m	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/03/11 07:58
End of Day Share Price	2026/03/11 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eupraxia Pharmaceuticals Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Martin	Bloom Burton & Co.
Tania Armstrong-Whitworth	Canaccord Genuity
Kristen Kluska	Cantor Fitzgerald & Co.